|
Monosomy
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Clonal heterogeneity and additional abnormalities including TP53 deletion and monosomies of
|
30678438 |
2019 |
|
Monosomy
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Multivariable survival modeling identified severe anemia (hemoglobin < 8.0 g/dL), NRAS mutation, SF3B1 mutation, TP53 mutation, elevated blast percentage (>10%), abnormal 3q, abnormal 9, and monosomy 7 as having the greatest survival risk.
|
30635634 |
2019 |
|
Monosomy
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition to known cytogenetic abnormalities, such as monosomy 13, hypodiploidy, and TP53 (17p) deletion, monosomy 16 and loss of the Y chromosome have adverse prognostic implications in patients with MM.
|
28089441 |
2017 |
|
Monosomy
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In group 4, CKS1B gain, RB1, or TP53 deletions had no additional impact on overall survival; however, trisomy 3 or 15 conferred a much better overall survival, and monosomy 13 and 14 predicted a worse outcome.
|
28281554 |
2017 |
|
Monosomy
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Among the ten patients with TP53 mutations who achieved a CR, nine presented with complex karyotypes due to abnormalities involving chromosome 5 and/or chromosome 7, and eight possessed monosomies.
|
27984642 |
2017 |
|
Monosomy
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Five cases with available modal karyotypes all demonstrated a complex karyotype involving the TP53 gene locus, with three cases (60%) also showing a monosomy 5 or deletion 5q and additional material on chromosome 19q13.
|
28261852 |
2017 |
|
Monosomy
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In this series, histone H3-K27M mutation was mutually exclusive with IDH1 mutation and EGFR amplification, rarely co-occurred with BRAF-V600E mutation, and was commonly associated with p53 overexpression, ATRX loss (except in pontine gliomas), and monosomy 10.
|
26517431 |
2016 |
|
Monosomy
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In 26/27 cases with TP53 mutation, the second TP53 allele was lost due to monosomy 17.
|
24619868 |
2014 |
|
Monosomy
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although overall chromosome 17 centromeric imbalances were not correlated with p53 overexpression (p=0.32), both cases with monosomy demonstrated high expression levels.
|
20414934 |
2010 |
|
Monosomy
|
0.100 |
GeneticVariation
|
group |
BEFREE |
SH-2 cells showed multiple drug resistance (MDR), which may be related to the p53 gene alteration, including the loss of one p53 allele due to the monosomy 17 and a point mutation of CAG to CAT at codon 576 of exon 5 in another p53 allele resulting in the loss of p53 gene function.
|
18715689 |
2008 |
|
Monosomy
|
0.100 |
GeneticVariation
|
group |
BEFREE |
82 samples from 81 patients were investigated to detect the deletion of TP53, RB1, CDKN2A genes, deletion of 1p36 and 19q13.3 region, amplification of EGFR gene, trisomy of chromosome 7 and monosomy of chromosome 10 in glial cells.
|
17569001 |
2007 |
|
Monosomy
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings indicate that loss of TP53 results from the absence of nearly the entire chromosome 17 p-arm rather than to monosomy 17 or deletions of TP53.
|
16737921 |
2006 |
|
Monosomy
|
0.100 |
Biomarker
|
group |
BEFREE |
FISH analysis revealed a significant percentage of cells with interspersed heterozygous deletions of TP53 in all tumors (14/14), ten cases showed also monosomy 17.
|
16391789 |
2006 |
|
Monosomy
|
0.100 |
Biomarker
|
group |
BEFREE |
The altered expression of PERP highlighted this apoptosis-specific target of p53 as a possible contributor to apoptosis in uveal melanoma with PERP downregulation being particularly relevant to the aggressive (monosomy 3) type of uveal melanoma.
|
16784742 |
2006 |
|
Monosomy
|
0.100 |
Biomarker
|
group |
BEFREE |
Specifically, unbalanced chromosome 17 monosomy in conjunction with p53 protein overexpression may constitute a valuable biomarker for progressive "field cancerization."
|
15064627 |
2004 |
|
Monosomy
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The gain or loss of copy number of chromosome 8 and monosomy 17 show parallel effects with c-myc amplification and p53 deletion, respectively, on the clinicopathological behavior of tumors.
|
14705768 |
2003 |
|
Monosomy
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Apart from the strong phenotypic impact of addition of acute myeloid leukemia/myelodysplasia-associated translocations and inversions, such as inv(3)(q21q26), t(3;21)(q26;q22), and t(15;17)(q22;q12-21), in CML BC, only a few significant differences between myeloid and lymphoid BC are discerned, with i(17q) and TP53 mutations being more common in myeloid BC and monosomy 7, hypodiploidy, and CDKN2A deletions being more frequent in lymphoid BC.
|
11919388 |
2002 |
|
Monosomy
|
0.100 |
Biomarker
|
group |
BEFREE |
Fluorescent in situ hybridization (FISH) analysis was used to detect monosomy for the 17 centromere and for the p53 locus.
|
12062821 |
2002 |
|
Monosomy
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We found inactivating p53 mutations in three (16%) cases, which correlated with a loss of p21(WAF1/Cip1) expression and with a monosomy of chromosome 17 in two cases.
|
11406642 |
2001 |
|
Monosomy
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In contrast to recently published FISH results, we only detected heterozygous p53 deletions in eight out of the 74 patients, three of them showing a monosomy 17.
|
10602435 |
1999 |
|
Monosomy
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In all cases, translocations led to a monosomy 17p and to a TP53 monoallelic deletion.
|
10086737 |
1999 |
|
Monosomy
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Chromosome 17 showed monosomy and exon 6 to 8 of p53 gene was not amplified by PCR, implying absence of p53 function.
|
10536176 |
1999 |
|
Monosomy
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We analysed genomic DNA and mRNA of the p53 gene in a case of myelodysplastic syndrome (MDS) with monosomy of chromosome 17.
|
9504641 |
1998 |
|
Monosomy
|
0.100 |
GeneticVariation
|
group |
BEFREE |
There was no clinical, or haematological difference or difference in survival between ras positive and ras negative patients with acute myeloid leukaemia (AML) in adults or children, but ras mutations carried a poorer prognosis in childhood acute lymphocytic leukaemia and an increased risk of leukaemia in MDS. p53 mutations predominated in lymphoid leukaemia and were several fold more frequent in leukaemia in relapse than in the de novo disease, were associated with loss of the normal p53 allele (monosomy 17) in > 50% of cases and carried a poor prognosis in AML, MDS and chronic lymphatic leukaemia and a 3.8-fold increase risk of death in T cell acute lymphocytic leukaemia.
|
9279367 |
1997 |
|
Monosomy
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our data suggest that mutations of the p53 gene occur in a minority of hemopoietic malignancies characterized by monosomy for the short arm of chromosome 17.
|
8152298 |
1994 |